Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Zhang, Sicai ^a,b   Berntsson, Ronnie P A ^c,d   Tepp, William H ^e   Tao, Liang ^a,b   Johnson, Eric A ^e   Stenmark, Pål ^c   Dong, Min ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BOTULINUM NEUROTOXIN DC; BOTULINUM TOXIN; GANGLIOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GM2; GANGLIOSIDE GM3; LIPOSOME; SIALIC ACID; SIALYL THOMSEN FRIEDENREICH ANTIGEN; SNARE PROTEIN; SYNAPSIN; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN 1; UNCLASSIFIED DRUG; BOTULINUM TOXIN TYPE C; BOTULINUM TOXIN TYPE D; N ACETYLNEURAMINIC ACID;

CELLS AND CELL COMPONENTS; CHEMICAL ANALYSIS; LIPID; MEMBRANE; NEUROLOGY; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARENT DISSOCIATION CONSTANT; ARTICLE; ASSAY; BINDING SITE; BRAIN CELL; BRAIN CELL CULTURE; CELL LYSATE; CELL MEMBRANE; CELL SURVIVAL; CRYSTAL STRUCTURE; HYDROGEN BOND; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LIPID MEMBRANE; LIPOSOME FLOTATION ASSAY; MOLECULAR RECOGNITION; MOUSE; NERVE CELL MEMBRANE; NERVE ENDING; NEUROTOXICITY; NEWBORN; NONHUMAN; POINT MUTATION; PROTEIN CLEAVAGE; PROTEIN LIPID INTERACTION; RAT; SUCROSE GRADIENT; SURVIVAL TIME; ANIMAL; BOTULISM; CHEMISTRY; FEMALE; HUMAN; MALE; METABOLISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BOTULINUM TOXINS; BOTULISM; CELL MEMBRANE; CRYSTALLOGRAPHY, X-RAY; FEMALE; GANGLIOSIDES; HUMANS; MALE; MICE; N-ACETYLNEURAMINIC ACID;

EID: 85034639606     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01534-z     Document Type: Article

References (49)

1. Schiavo, G., Matteoli, M. &Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
2. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79, 591-617 (2010).
3. Arnon, S. S. et al. Botulinum toxin as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285, 1059-1070 (2001).
4. Schiavo, G. et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832-835 (1992).
5. Brunger, A. T. &Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 54, 550-560 (2009).
6. Sollner, T. et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 362, 318-324 (1993).
7. Sudhof, T. C. &Rothman, J. E. Membrane fusion: grappling with SNARE and SM proteins. Science 323, 474-477 (2009).
8. Sutton, R. B., Fasshauer, D., Jahn, R. &Brunger, A. T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395, 347-353 (1998).
9. Dolly, J. O., Lawrence, G. W., Meng, J. &Wang, J. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 9, 326-335 (2009).
10. Montecucco, C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 314-317 (1986).
11. Simpson, L. L. &Rapport, M. M. Ganglioside inactivation of botulinum toxin. J. Neurochem. 18, 1341-1343 (1971).
12. Nishiki, T. et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498-10503 (1994).
13. Dong, M. et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162, 1293-1303 (2003).
14. Rummel, A., Karnath, T., Henke, T., Bigalke, H. &Binz, T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 279, 30865-30870 (2004).
15. Dong, M., Tepp, W. H., Liu, H., Johnson, E. A. &Chapman, E. R. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 179, 1511-1522 (2007).
16. Jin, R., Rummel, A., Binz, T. &Brunger, A. T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095 (2006).
17. Chai, Q. et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100 (2006).
18. Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596 (2006).
19. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. &Binz, T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014 (2006).
20. Dong, M. et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226-5237 (2008).
21. Peng, L., Tepp, W. H., Johnson, E. A. &Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).
22. Rummel, A. et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 110, 1942-1954 (2009).
23. Fu, Z., Chen, C., Barbieri, J. T., Kim, J. J. &Baldwin, M. R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641 (2009).
24. Yeh, F. L. et al. SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 6, e1001207 (2010).
25. Strotmeier, J. et al. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol. Microbiol. 81, 143-156 (2011).
26. Karalewitz, A. P., Fu, Z., Baldwin, M. R., Kim, J. J. &Barbieri, J. T. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J. Biol. Chem. 287, 40806-40816 (2012).
27. Wang, B. &Brand-Miller, J. The role and potential of sialic acid in human nutrition. Eur. J. Clin. Nutr. 57, 1351-1369 (2003).
28. Yamashita, T. et al. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. USA 102, 2725-2730 (2005).
29. Sheikh, K. A. et al. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl. Acad. Sci. USA 96, 7532-7537 (1999).
30. Yamashita, T. et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA 100, 3445-3449 (2003).
31. Takamiya, K. et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc. Natl. Acad. Sci. USA 93, 10662-10667 (1996).
32. Kitamura, M., Takamiya, K., Aizawa, S. &Furukawa, K. Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim. Biophys. Acta 1441, 1-3 (1999).
33. Bullens, R. W. et al. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 22, 6876-6884 (2002).
34. Tsukamoto, K. et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J. Biol. Chem. 280, 35164-35171 (2005).
35. Strotmeier, J. et al. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 431, 207-216 (2010).
36. Rummel, A., Mahrhold, S., Bigalke, H. &Binz, T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51, 631-643 (2004).
37. Rummel, A., Bade, S., Alves, J., Bigalke, H. &Binz, T. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 326, 835-847 (2003).
38. Stenmark, P., Dupuy, J., Imamura, A., Kiso, M. &Stevens, R. C. Crystal structure of botulinum neurotoxin type A in complex with the cell surface coreceptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4, e1000129 (2008).
39. Berntsson, R. P., Peng, L., Dong, M. &Stenmark, P. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 4, 2058 (2013).
40. Benson, M. A., Fu, Z., Kim, J. J. &Baldwin, M. R. Unique ganglioside recognition strategies for clostridial neurotoxins. J. Biol. Chem. 286, 34015-34022 (2011).
41. Kroken, A. R. et al. Unique ganglioside binding by botulinum neurotoxins C and D-SA. FEBS J. (2011).
42. Hill, K. K. et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 189, 818-832 (2007).
43. Hill, K. K., Xie, G., Foley, B. T. &Smith, T. J. Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107, 2-8 (2015).
44. Peng, L. et al. Botulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins. J. Cell Sci. (2012).
45. Berntsson, R. P., Peng, L., Svensson, L. M., Dong, M. &Stenmark, P. Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II. Structure 21, 1602-1611 (2013).
46. Nuemket, N. et al. Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: Insight into the ganglioside binding mechanism. Biochem. Biophys. Res. Commun. 411, 433-439 (2011).
47. Boroff, D. A. &Fleck, U. Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum. J. Bacteriol. 92, 1580-1581 (1966).
48. Bennett, M. K., Calakos, N., Kreiner, T. &Scheller, R. H. Synaptic vesicle membrane proteins interact to form a multimeric complex. J. Cell Biol. 116, 761-775 (1992).
49. Liu, Y. et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 103, 497-505 (1999).